Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 9189483, 9 pages
http://dx.doi.org/10.1155/2016/9189483
Review Article

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

1Interdisziplinäres Tumorzentrum, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
2Department of Surgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
3Krebszentrum Reutlingen, Reutlingen, Germany
4University of Pisa, Pisa, Italy
5Department of Nursing and Health, University of Applied Sciences of the Saarland, Saarbrücken, Germany
6University Cancer Center Leipzig (UCCL), Universitätsklinikum Leipzig, Leipzig, Germany

Received 14 March 2016; Accepted 19 July 2016

Academic Editor: Alessandro Passardi

Copyright © 2016 R.-D. Hofheinz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Figures S1 and S2: Metaanalyses for progression-free and overall survival according to age. CI: Confidence interval; hr: Hazard ratio; yrs: years

Figures S3 and S4: Metaanalyses for progression-free and overall survival according to gender. CI: Confidence interval; hr: Hazard ratio; yrs: years

Figures S5 and S6: Metaanalyses for progression-free and overall survival according to Eastern Cooperative Oncology Group Performance (ECOG) status. CI: Confidence interval; hr: Hazard ratio; 0: ECOG 0; >=1: ECOG status ≥ 1

Figures S7 and S8: Metaanalyses for progression-free and overall survival according to KRAS mutational status. CI: Confidence interval; hr: Hazard ratio; WT: KRAS wildtype tumor; mutated: tumor harboring KRAS mutation

Figures S9 and S10: Metaanalyses for progression-free and overall survival according to substance class used (monoclonal antibody, mAB, tyrosine kinase inhibitor, TKI). CI: Confidence interval; hr: Hazard ratio.

  1. Supplementary Material